A year after starting the IPO process, PeptiDream Inc. hopes it will still be able to benefit from Japan's biotech bubble when the cyclic peptide play lists on June 11 (see BioCentury, Feb. 11).

Earlier this month, PeptiDream said it plans to sell 1.7 million shares at ¥1,720-¥1,920 in an IPO on the Tokyo Stock Exchange's market of the high-growth and emerging stocks (Mothers).